An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

Addictive Behaviors
Charles S WilcoxEduardo Dunayevich

Abstract

A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain. Thirty overweight or obese nicotine-dependent subjects were enrolled in a 24-week, open-label study; 85% and 63% completed 12 and 2 4weeks, respectively. The target quit date was Week 4. Week 4-12 continuous abstinence rate was 48%, 78% of subjects achieved CO < or = 10 ppm, serum cotinine decreased from 185 to 48 microg/L, and tobacco use decreased from 129 to 14 cigarettes/week. Similar results were seen at Week 24. Body weight was essentially unchanged (Week 12: -0.1%; Week 24: +0.4%). Except for a transient significant increase 1 week after the target quit date (p<0.05), nicotine withdrawal scores did not change. The most common adverse events were nausea, insomnia, and constipation. These tended to be transient and mild or moderate in severity. In overweight or obese smokers, naltrexone/bupropion combination therapy with behavioral counseling was associated with decreased nicotine use, limited nicotine withdrawal symptoms, and no significant weight gain.

References

Mar 1, 1986·Archives of General Psychiatry·J R Hughes, D Hatsukami
Oct 23, 1997·The New England Journal of Medicine·R D HurtP M Sullivan
Mar 4, 1999·The New England Journal of Medicine·D E JorenbyT B Baker
Jul 10, 2002·Obesity Research·James W AndersonPatrick M O'Neil
Apr 17, 2004·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·C FilozofA Fernández-Cruz
Sep 15, 2004·Archives of Internal Medicine·Joel A SimonEsther S Hudes
Mar 29, 2006·Archives of Internal Medicine·Stephanie S O'MalleyPeter Jatlow
Jul 6, 2006·JAMA : the Journal of the American Medical Association·David GonzalesUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Douglas E JorenbyUNKNOWN Varenicline Phase 3 Study Group
Jun 26, 2007·Addictive Behaviors·Benjamin A TollStephanie S O'Malley
Jul 16, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Mark J EisenbergLouise Pilote
Nov 11, 2008·Obesity·Frank L GreenwayMichael A Cowley
Dec 17, 2008·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Oct 23, 2009·The Journal of Clinical Endocrinology and Metabolism·Frank L GreenwayUNKNOWN NB-201 Study Group

❮ Previous
Next ❯

Citations

May 25, 2011·Drug Design, Development and Therapy·José Juan Escobar-ChávezIsabel Marlen Rodríguez-Cruz
Apr 12, 2011·CNS Drugs·Tobias Raupach, Constant P van Schayck
Mar 13, 2012·Contemporary Clinical Trials·Ivana T CroghanRichard D Hurt
Jun 22, 2011·Expert Opinion on Pharmacotherapy·Sonja K Billes, Frank L Greenway
Apr 24, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Sonja K BillesMichael A Cowley
Aug 20, 2016·Journal of the American College of Cardiology·Matthew H VorsangerArthur Z Schwartzbard
Nov 13, 2015·The American Journal of Clinical Nutrition·Robin P ShookSteven N Blair
Nov 17, 2017·Nature Reviews. Neuroscience·Nora D VolkowRuben Baler
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Amanda C FarleyPaul Aveyard
Apr 16, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Farah E KhorassaniShauna Garris
Mar 30, 2016·Applied Microbiology and Biotechnology·Sarah Calcagno, Christian D Klein
Dec 19, 2013·Journal of Clinical Psychopharmacology·John SramekNeal R Cutler
Apr 23, 2020·The Cochrane Database of Systematic Reviews·Seth HowesNicola Lindson
May 22, 2020·Circulation Research·Sean P HeffronJosé O Alemán
May 24, 2016·Clinical Pharmacology and Therapeutics·M E MooneyD K Hatsukami
Jun 21, 2017·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Vignesh ShettarSrividya Kidambi
Jun 8, 2013·The Cochrane Database of Systematic Reviews·Sean P DavidJudith J Prochaska
Jan 1, 2019·Current Addiction Reports·Ariana M ChaoHeath D Schmidt
Oct 7, 2021·The Cochrane Database of Systematic Reviews·Jamie Hartmann-BoycePaul Aveyard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.